AE Monitoring and Management With Targeted Therapies in NSCLC

December 6, 2024

Opinion

Video

Panelists discuss how ongoing trials may reshape the treatment landscape for HER2-altered NSCLC, particularly regarding the roles of ADCs and TKIs in managing both HER2-mutated and HER2-overexpressing NSCLC.

EP: 1.An Overview of HER2 Alterations in NSCLC and Implications for Treatment

EP: 2.Biomarker Testing in NSCLC: Best Practices for Personalized Medicine

EP: 3.T-DXd in HER2-Overexpressing and HER2-Mutated NSCLC: Clinical Trial Data and Insights

EP: 4.ADCs, TKIs, and the Evolving Treatment Landscape in HER2-Altered NSCLC

Now Viewing

EP: 5.AE Monitoring and Management With Targeted Therapies in NSCLC

EP: 6.Thoracic Oncologist Perspectives on a Rapidly Evolving Treatment Landscape

EP: 7.Identifying HER2 Mutations for T-DXd Use in NSCLC

(Rohit asks Levy) Please briefly highlight other trials of note and how the treatment landscape in HER2-altered NSCLC may evolve over time. What might be the positioning of ADCs, TKIs, and other treatment modalities in the treatment landscapes for HER2-mutated and HER2-overexpressing NSCLC?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!